托伐普坦治疗恶性腹腔积液合并低钠血症的临床观察

发布时间：2018-10-20 09:38

【摘要】：目的:观察托伐普坦治疗恶性腹腔积液合并低钠血症患者后的血钠及24 h尿量等指标变化。方法:38例恶性腹腔积液合并低钠血症患者随机分为观察组和对照组,对照组给予常规利尿处理,观察组在常规治疗基础上联用托伐普坦片,治疗7 d后,比较两组患者治疗前后血钠、24 h尿量、腹围及体重等指标的变化,并观察治疗期间两组不良反应发生情况。结果:治疗后观察组的血钠水平较治疗前显著升高(P0.01),治疗后两组24 h尿量均较治疗前增多(P0.01),且治疗后观察组24 h尿量明显高于对照组(P0.01)。观察组4例患者出现口干不适,两组间差异无统计学意义,治疗期间两组患者均未出现严重不良反应。结论:托伐普坦治疗恶性腹腔积液合并低钠血症患者的疗效确切,可以改善患者的生存质量,且安全可靠。
[Abstract]:Objective: to observe the changes of blood sodium and 24 h urine volume after treatment of malignant peritoneal effusion with hyponatremia. Methods: Thirty-eight patients with malignant peritoneal effusion combined with hyponatremia were randomly divided into two groups. The control group was treated with routine diuretic treatment, and the observation group was treated with Tofaptan tablet on the basis of routine treatment for 7 days. The changes of serum sodium, 24 h urine volume, abdominal circumference and body weight before and after treatment were compared between the two groups. Results: after treatment, the serum sodium level in the observation group was significantly higher than that before treatment (P0.01), and the urine volume at 24 h after treatment in both groups was higher than that before treatment (P0.01), and the urine volume in the observation group at 24 h after treatment was significantly higher than that in the control group (P0.01). There were 4 cases of dry mouth discomfort in the observation group, but there was no significant difference between the two groups. There were no serious adverse reactions in both groups during the treatment period. Conclusion: the treatment of malignant peritoneal effusion with hyponatremia is effective, and can improve the quality of life, and is safe and reliable.
【作者单位】：华中科技大学同济医学院附属同济医院综合肿瘤科;
【基金】：国家自然科学基金(81202095) 高等学校博士学科点专项科研基金(20120142120053)
【分类号】：R730.5

【相似文献】